Group 1 - The core point of the article highlights that Crystal Tech Holdings (02228) saw a significant stock price increase, rising over 5% and reaching HKD 11.03, with a trading volume of HKD 1.487 billion [1] - Crystal Tech Holdings has been included in the FTSE China Small Cap Index as part of the FTSE Russell Index Company's semi-annual adjustments, effective after the market close on September 19 [1] - Inclusion in an international index indicates broader capital attention and liquidity premium for the company [1] Group 2 - According to招商证券, Crystal Tech's AI pharmaceutical business is steadily advancing towards commercialization, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1] - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - Crystal Tech has signed a pipeline cooperation agreement with DoveTree, with a total order scale of USD 5.99 billion, and has received an initial payment of USD 51 million, contributing positively to its performance [1] Group 3 - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physical computing, multimodal AI, and automation platforms [1]
港股异动 | 晶泰控股(02228)尾盘涨超5% 公司获纳入富时中国小盘股 AI制药业务商业化稳步推进